KPIs & Operating Metrics(New)
Growth Metrics

Xylem (XYL) EBT (2016 - 2026)

Xylem has reported EBT over the past 17 years, most recently at $244.0 million for Q1 2026.

  • For Q1 2026, EBT rose 12.44% year-over-year to $244.0 million; the TTM value through Mar 2026 reached $1.2 billion, up 9.03%, while the annual FY2025 figure was $1.2 billion, 8.65% up from the prior year.
  • EBT for Q1 2026 was $244.0 million at Xylem, down from $368.0 million in the prior quarter.
  • Over five years, EBT peaked at $375.0 million in Q4 2024 and troughed at $17.0 million in Q3 2022.
  • A 5-year average of $211.0 million and a median of $210.0 million in 2023 define the central range for EBT.
  • Biggest five-year swings in EBT: plummeted 87.22% in 2022 and later surged 988.24% in 2023.
  • Year by year, EBT stood at $189.0 million in 2022, then rose by 11.11% to $210.0 million in 2023, then soared by 78.57% to $375.0 million in 2024, then decreased by 1.87% to $368.0 million in 2025, then tumbled by 33.7% to $244.0 million in 2026.
  • Business Quant data shows EBT for XYL at $244.0 million in Q1 2026, $368.0 million in Q4 2025, and $297.0 million in Q3 2025.